Skip to content

Study Details

ALVR P-105-202: A Study Drug for People at Risk for Viruses after Allogeneic Hematopoietic Cell Transplant (CHT)

(IRB#: IRB_00158589)

Allogeneic Hematopoietic Cell Transplant (CHT) is done to replace a persons bone marrow thats not producing enough healthy blood cells. The transplant can cause a higher risk for specific viral infections and/or diseases. ALVR P-105-202 is a study drug to help reduce the risk of severe health conditions after CHT. Research is needed to learn the safety and effectiveness of ALVR P-105-202. The information we gain may aid future patients.

I AM INTERESTED

  • All genders
  • All Ages
  • Volunteers with special conditions
  •   In Person
  • Paid

Who can participate?

 Gender: All genders

  Age: All Ages

  Volunteers: Volunteers with special conditions

   Location: In Person

Inclusion Criteria

  • Ages 1 year and older
  • Be within 15-42 days of receiving a first allogeneic procedure
  • At high risk for specific viral infections
  • Attend the University of Utah

Exclusion Criteria

  • Current or history of other specific viral infections and/or diseases that may alter study results
  • Pregnant or breastfeeding

Will I be paid for my time?

Yes

For more information contact:

Priscilla Rosen

priscilla.rosen@hsc.utah.edu

  801-213-3401

IRB#: IRB_00158589

PI: AHMAD RAYES

Department: PEDIATRIC HEMATOLOGY/ONCOLOGY

Approval Date: 2023-04-26 06:00:00

Specialties: Pediatric Hematology & Oncology

Last Updated: 6/8/23